What Happened With This Assignment

Since our tariff coverage began in early June, we've tracked five separate stories in that space. Today's assignment asked us to pivot to a health topic — specifically, whether GLP-1 agonists like Ozempic and Wegovy may reduce cancer risk in people with obesity.

There's one problem. We have nothing to work with.

The single source tagged to this health topic — a Medscape article — returned a 404 Page Not Found error. No headline. No data. No author. No study citation. Nothing.

The other two sources covered Trump's tariff and trade policy. Completely unrelated.

Why We're Not Publishing Without Facts

GLP-1 receptor agonists are a massive story. Semaglutide — sold as Ozempic for diabetes and Wegovy for weight loss — generated over $13.8 billion in revenue for Novo Nordisk in 2024 alone, according to Novo Nordisk's own annual report. Eli Lilly's tirzepatide (Mounjaro, Zepbound) is right behind it.

Research into whether these drugs reduce cancer incidence is genuinely active and genuinely important. Studies published in journals including JAMA Network Open and Nature Medicine have explored associations between GLP-1 use and reduced rates of certain obesity-related cancers. That's a real conversation happening in the medical literature.

But a conversation happening is not the same as having specific, sourced, attributable facts in hand.

We don't print health claims — especially ones involving drugs millions of Americans are taking — without being able to name the study, name the lead researcher, cite the sample size, and tell you exactly what was and wasn't proven.

What Mainstream Health Media Gets Wrong Here

This is the core problem with GLP-1 coverage across the board right now. Outlets ranging from CNN Health to WebMD routinely publish stories framed as "GLP-1 drugs may do X" based on preliminary observational data, without clearly telling readers:

• Whether it was a randomized controlled trial or an observational study (huge difference)
• Whether the effect was statistically significant or just a trend
• Whether the researchers controlled for other variables like diet, activity, and comorbidities
• Who funded the research (Novo Nordisk and Eli Lilly fund a LOT of this research)

The typical reader walks away thinking their weight-loss drug also prevents cancer. The nuance gets lost every single time.

The Funding Question Nobody Wants to Ask

Novo Nordisk and Eli Lilly have a combined market capitalization north of $800 billion. They have every financial incentive to see GLP-1 drugs prescribed for cancer prevention, cardiovascular protection, kidney disease, addiction, and whatever else the next study suggests.

That doesn't make the science wrong. It means you should know who's paying for it before you treat the findings as gospel.

Independent replication matters. Peer review matters. Long-term follow-up data matters. A single Medscape article that no longer exists at its URL tells you nothing.

What We'll Do Instead

When credible, sourced, attributable reporting on GLP-1 drugs and cancer risk is available — with a named study, a named lead author, a named journal, and a clear methodology — we'll cover it properly.

Until then, we're not speculating. We're not summarizing a 404 error. And we're not telling you a drug "may" do something based on a page that doesn't exist.